Approximately 50%–60% of NSCLC patients have at least one identifiable driver mutation, with the most common mutations found in the Kirsten ras (KRAS) gene (25–30%) and the epidermal growth factor receptor (EGFR) gene (13–22%), along with translocations involving anaplastic lymphoma kinase (ALK) gene in another 5–6% cases [2–5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.